Evaluation of long-term outcomes in patients with osteomyelitis treated with a daptomycin-containing regimen

Internet Journal of Infectious Diseases

Volumn 7, Issue 2, 2010, Pages 5-

  Balter, Laurence ^a   Donovan, Brian J ^b   Lamp, Kenneth C ^b   North, Donald S ^b   Friedrich, Lawrence V ^b  

^a GE Davis and Associates   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Daptomycin; MRSA; Osteomyelitis

Indexed keywords

C REACTIVE PROTEIN; DAPTOMYCIN; ERTAPENEM; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ADULT; ALLERGY; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYALGIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; OUTCOME ASSESSMENT; PAPILLEDEMA; RADIOGRAPHY; REVIEW; RHABDOMYOLYSIS; TREATMENT DURATION;

EID: 77953437715     PISSN: None     EISSN: 15288366     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364:369-379.
2. Gottlieb T, Atkins BL, Shaw DR. Soft tissue, bone and joint infections. Med J Aust 2002;176:609-615.
3. Bamberger DM, Boyd SE. Management of Staphylococcus aureus infections. Am Fam Physician 2005;72:2474-2481.
4. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003;114:723-728.
5. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38:521-528.
6. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr., Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-2402.
7. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989;33:689-692.
8. Luu QN, Buxton TB, Nelson DR, Rissing JP. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol Infect Dis 1989;8:562-563.
9. Rouse MS, Piper KE, Jacobson M, Jacofsky DJ, Steckelberg JM, Patel R. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006;57:301-305.
10. Dretler R, Branch T. MRSA knee infection treated successfully with daptomycin after two failed prolonged high-dose courses of vancomycin. Infect Dis Clin Pract 2006;13:327-329.
11. Burns CA. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis 2006;38:133-136.
12. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin 2005;21:1923-1926.
13. Antony SJ, Angelos E, Stratton CW. Clinical experience with daptomycin in patients with orthopedic-related infections. Infect Dis Clin Pract 2006;14:144-149.
14. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007;120:S13-S20.
15. Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents 2007;30:202-209.
16. Lalani T, Boucher HW, Cosgrove SE, Fowler VG, Kanafani ZA, Vigliani GA, Campion M, Abrutyn E, Levine DP, Price CS, Rehm SJ, Corey GR, Karchmer AW. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61:177-182.
17. Rolston KV, Segreti J, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med 2007;120:S4-S5.
18. Berbari EF, Steckelberg JM, Osmon DR. Osteomyelitis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 6th ed. Philadelphia, PA: Elsevier Inc., 2005, pp 1322-1332.
19. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005;9:127-138.
20. Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs 2006;66:1089-1105.
21. Shuford JA, Steckelberg JM. Role of oral antimicrobial therapy in the management of osteomyelitis. Curr Opin Infect Dis 2003;16:515-519.
22. Holtom PD, Zamorano D, Patzakis MJ. Osteomyelitis attributable to vancomycin-resistant enterococci. Clin Orthop 2002;38-44.